neurodegenerative disease
Patients dismayed as FDA advisors narrowly reject Amylyx’ ALS drug
Phil Taylor
Amylyx, amyotrophic lateral sclerosis, fda, neurodegenerative disease, neurology
0 Comment
Amylyx slumps on non-committal FDA reviewer assessment of ALS drug
Phil Taylor
Amylyx, amyotrophic lateral sclerosis, central nervous system, neurodegenerative disease
0 Comment
Blow to Biogen as ALS hope tofersen flunks phase 3 trial
Phil Taylor
ALS, Biogen, neurodegenerative disease, tofersen
0 Comment
Bad news for Biohaven as verdiperstat flunks first phase 3 test
Phil Taylor
Biohaven Pharmaceuticals, multiple system atrophy, neurodegenerative disease, rare disease, verdiperstat
0 Comment
AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trial
Phil Taylor
Alexion, amyotrophic lateral sclerosis, AstraZeneca, complement therapeutics, neurodegenerative disease, Soliris, UCB, Ultomiris, zilucoplan
0 Comment
Ipsen forges $1bn alliance with Exicure on neurodegenerative diseases
Phil Taylor
Angelman Syndrome, Exicure, Huntington's disease, Ipsen, neurodegenerative disease, partnering, rare disease
0 Comment
Healx deploys its AI in hunt for Friedreich’s ataxia therapies
Phil Taylor
artificial intelligence, ataxia, digital, digital health, Friedreich's ataxia, Healx, neurodegenerative disease, patient organisation
0 Comment
AI drug discovery firm Valence joins Parkinson’s disease push
Phil Taylor
artificial intelligence, central nervous system, digital, digital health, drug discovery, neurodegenerative disease, Parkinson's disease, Valence Discovery
0 Comment